Received Nov 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
when tested for immunity, she was not shown to be immune; This spontaneous report was received from consumer and refers to a 20-year-old female patient (her daughter). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient completed the original series when she was younger of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) as prophylaxis (dose, route, scheme, lot number and expiration date not reported). On unspecified date, when tested for immunity, she was not shown to be immune (Immunology test abnormal). It was reported that at the reporting time, was in the process of re-vaccination as first 2 doses when she was 19 and at the time of the report, she was 20 years old in the process of her revaccination for Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). The outcome of the event was not indicated. The causal relationship between the event and suspect vaccine was not reported.